Tumor Necrosis factor receptor

Fc fusion protein does not improve septic shock and may increase mortality in human

Authors

  • Álvaro Nagib Atallah Universidade Federal de São Paulo

Downloads

Download data is not yet available.

Author Biography

Álvaro Nagib Atallah, Universidade Federal de São Paulo

MD, PhD, MSc Department of Internal Medicine, Escola Paulista de Medicina Chairman, Editor, São Paulo Medical Journal.

References

Fisher CJ, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc Fusion Protein. N Engl J Med 1996;334:1697-702.

Trace KJ, Beuther B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-4.

Feinberg B, Kurzrock R, Talpaz M, Blicks M, Saks S, Gutterman JU. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988;6:1328-34.

Beutler B, Milsark IW, Ceramio AC. Passive immunization against cachectin/ tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985;229:869-71.

Walsh CJ, Sugerman HJ, Mullen PG, et al. Monoclonal antibody to tumor necrosis factor alpha attenuates cardiopulmonary dysfunction in porcine gram-negative sepsis. Arch Surg 1992;127:138-45.

Downloads

Published

1996-05-05

How to Cite

1.
Atallah Álvaro N. Tumor Necrosis factor receptor: Fc fusion protein does not improve septic shock and may increase mortality in human. Sao Paulo Med J [Internet]. 1996 May 5 [cited 2025 Oct. 16];114(3):1151. Available from: https://periodicosapm.emnuvens.com.br/spmj/article/view/2001

Issue

Vol. 114 No. 3 (1996)

Section

Editorial

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.